Immpact Bio USA

Immpact Bio USA

Founded by a scientific team drawn from the cell-therapy research community, Immpact Bio USA operates from Camarillo, California, developing engineered T-cell therapies that address antigen escape and on-target, off-tumor toxicity — the two main reasons CAR-T has not yet translated broadly to solid tumors. Its foundational intellectual property centers on a logic-gated, dual-targeting approach that requires two separate tumor antigens to be present before full T-cell activation occurs, a mechanism intended to leave healthy cells unharmed even if they express one of the targets. This focus places the firm squarely within a highly technical, capital-intensive segment of the biotech market where clinical data, manufacturing consistency, and intellectual-property moats determine differentiation. The company's lead program targets BCMA and a secondary undisclosed antigen for multiple myeloma, a disease where single-target CAR-T therapies from larger players have faced relapse due to antigen loss. The firm has presented preclinical data at major industry conferences demonstrating that its dual-gating technology can reduce off-target cytokine release in vitro. In September 2023, the company closed a $60 million Series B co-led by venBio Partners and Foresite Capital, with participation from new investor BMS and existing backers (per the firm, September 2023). The financing was earmarked to advance the lead multiple myeloma candidate through IND-enabling studies and into a first-in-human Phase 1/2 trial. The firm maintains wet-lab and process-development facilities in Camarillo, where it runs internal manufacturing for clinical supply. Adjacent scientific infrastructure includes partnerships with academic medical centers for translational immunology and tumor-model validation, a standard model for pre-revenue biotechs in this space. Team disclosures remain limited; the scientific founders hold academic appointments and have published extensively in Nature Medicine and Science Translational Medicine on synthetic-biology circuits for T cells. The board composition following the Series B includes representatives from venBio and Foresite, standard for a venture-backed therapeutics company at this stage. A key structural differentiator for Immpact Bio is its exclusive focus on intracellular signaling rewiring rather than relying solely on external antigen binders. Whereas most logic-gated CAR-Ts use synNotch or small-molecule switches that add complexity to the extracellular domain, the firm's system integrates the gate at the signaling level, which can reduce construct size and potentially improve in vivo persistence. This design departs from the architectures pursued by larger players, including those that have discontinued solid-tumor CAR-T programs after clinical failures. The same signaling-first approach is being applied to a solid-tumor pipeline that remains in discovery, targeting tumor microenvironments where single-antigen strategies have produced unacceptable toxicity profiles.